Current Medicaid Coverage for Weight-Loss Medications
In a recent survey, it has been revealed that most Medicaid programs across the United States do not provide coverage for popular weight-loss medications developed by Novo Nordisk (NYSE: NVO) and Eli Lilly (NYSE: LLY). Cost considerations are highlighted as a significant barrier to broader coverage, according to insights gathered by health research organization KFF.
Survey Findings on Coverage
The survey, which encompasses all 50 states and the District of Columbia, disclosed that only 12 Medicaid programs currently offer coverage for obesity treatment medications. This limited access comes with restrictions for beneficiaries. Notably, half of the states that do not cover these weight-loss drugs are either contemplating their inclusion in Medicaid plans or assessing the existing coverage policies.
Understanding GLP-1 Agonists
The medications in question belong to the class of drugs known as GLP-1 agonists, originally formulated for managing type 2 diabetes. These drugs assist in weight management by suppressing appetite, contributing to significant weight loss. Novo's Wegovy and Lilly's Zepbound are currently priced at approximately $1,000 per month, although many patients face lower out-of-pocket costs due to insurance coverage or discounts from the manufacturers.
Commercial and Medicare Coverage Limitations
Coverage for these weight-loss medications through commercial insurance plans is also restrictive. For seniors aged 65 and over, the Medicare program has posited that GLP-1 drugs could be covered if utilized for diabetes management and cardiovascular issues, following positive findings from recent studies regarding heart health benefits.
Financial Projections for Medicaid Programs
According to KFF, state Medicaid programs foresee a 7% increase in health plan spending for the fiscal year 2025. This projected rise represents a deceleration from the 19% surge experienced the previous year, primarily due to declining membership numbers. Generally, the fiscal year for most participating states concludes on June 30.
Impact of Policy Changes and Funding Expiration
The significant moderation in spending growth is attributed to the cessation of the policy which mandated insurers to keep members active during the pandemic, coupled with the end of certain federal funding avenues. Medicaid expenses are jointly funded by state revenues and federal contributions. Overall Medicaid expenditures climbed by 5.5% in fiscal 2024 and are expected to rise by 3.9% in the forthcoming year.
Membership Shifts in Medicaid
Following the re-determination of Medicaid memberships, enrollment levels witnessed a decline from a peak of 94 million in April 2023, with around 71 million individuals covered before the pandemic. As of August, four states continued to review Medicaid eligibility for their residents. The KFF survey anticipates a further membership decline of approximately 4.4% for 2025, slightly improved from a projected drop of 7.5% in 2024.
Challenges with Rising Healthcare Costs
The survey identified rising costs associated with healthcare providers, managed care, medical benefits, and medication as substantial factors motivating spending increases. Furthermore, about three-quarters of states are currently investigating new initiatives aimed at curbing prescription drug prices for the years 2024 and 2025, reflecting a proactive approach to tackling escalating healthcare expenses.
Frequently Asked Questions
What are GLP-1 agonists?
GLP-1 agonists are medications that were primarily developed for treating type 2 diabetes, but they also aid in weight loss by reducing appetite.
Why aren't weight-loss drugs widely covered by Medicaid?
The main reason for limited coverage is the high cost associated with these medications, which many state Medicaid programs find unmanageable.
How many states currently cover weight-loss medications?
Only 12 of the Medicaid programs across the U.S. currently offer coverage for weight-loss drugs, and even these have some restrictions.
What financial trends are expected in the future for Medicaid?
State Medicaid programs expect their health spending to grow by 7% in fiscal 2025, which is a decrease from previous years due to lower enrollment numbers.
How are states responding to rising drug costs?
Many states are exploring new initiatives to manage and reduce prescription drug expenses as part of their healthcare budgets.
